AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06418438 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic uterosacral ligament suspension with hysterectomy
Description: After anesthesia, bladder stone removal patients undergo laparoscopic hysterectomy. The adnexa are coagulated and cut, and the bladder peritoneal reflection is opened. The uterus is removed transvaginally. Next, laparoscopic uterosacral ligament suspension is performed. The right and left uterosacral ligaments are freed and sutured to lift the residual end.
Study NCT06418438 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic uterosacral ligament suspension with cervical amputation
Description: After anesthesia, bladder stone removal patients undergo cervical amputation surgery. The cervix is exposed and elevated using Allis forceps. A dilator is used to expand the cervix, and an incision is made on the anterior vaginal wall. The cervix is excised and shaped using the Sturmdorf method. Afterward, laparoscopic uterosacral ligament suspension is performed. The right and left uterosacral ligaments are freed and sutured to lift the uterus.
Study NCT05651932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort A1 & A2
Description: KTX-1001 will be administered orally for 28 days each cycle until progression. Dexamethasone: Orally once weekly
Study NCT05651932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort C1 & C2
Description: KTX-1001: Orally for 28 days each cycle until progression Carfilzomib: IV, once weekly for 3 weeks in each 28-day cycle Dexamethasone: Orally once weekly
Study NCT05651932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort D
Description: KTX-1001: Orally daily for 28 days each cycle until progression Pomalidomide: Orally, for 21 days in each 28-day cycle Dexamethasone: Orally once a week
Study NCT06132854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR
Description: The virtual environment is provided by the Oculus Quest 2 or 3 VR headset, providing a high-quality and immersive visual experience.
Study NCT06132854 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Booklet
Description: Children in the booklet condition will be prepared by using an educational booklet containing colorful illustrations of the MRI examination room and about the procedure.
Study NCT05169125 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard hemodialysis
Description: patients who will undergo standard hemodialysis (dialysate sodium concentration 143 mmoL/L)
Study NCT05169125 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lower dialysate sodium dialysis
Description: patients who will undergo hemodialysis with lower dialysate sodium concentration (140 mmoL/L)
Study NCT05182996 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: smoking education
Description: Educate on the relationship between inflammatory bowel disease and smoking and the necessity and importance of quitting smoking.
Study NCT05055414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UI030
Description: Budesonide/Arformoterol dry powder inhaler, 3 inhalations b.i.d at 3 days and 2 inhalations b.i.d at 11 days
Study NCT05055414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UI030
Description: Budesonide/Arformoterol dry powder inhaler, 3 inhalations b.i.d at 3 days and 2 inhalations b.i.d at 11 days
Study NCT05543655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high fidelity simulation
Description: Each half-day training session will begin with a reminder of the context and general objectives of the training. Nurses will complete the self-assessment and knowledge tests.~The nurses, each in turn, will start the scenario and will immediately assess the workload felt, by the Nasa-TLX grid. During these high-fidelity simulation sessions, an error cart workshop will allow all the other nurses to summon up their knowledge on safety tools upstream of the administration procedure.~The session begins with a briefing and ends with a debriefing.
Study NCT06249945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: The medication will be packed in a customized sealed jar and labeled on the exterior of the jar.
Study NCT06249945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo tablet is manufactured by Prince Pharmaceutical Co., Ltd, a leading manufacturer of nutritional supplements with certifications including cGMP, GMP, ISO, and HACCP. The Prince Pharmaceutical also provides Original Equipment Manufacturing (OEM)/Original Design Manufacturing (ODM) services for a wide array of tablet shapes, and post-processing techniques such as film coating and sugar coating.
Study NCT05757115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Play Skills Training
Description: Each parent will be provided with play skills training that will support them to spend effective and meaningful time with their child. While planning the educational contents, an Occupational Therapy Model suitable for the parent and the child will be used. The process will be followed by giving unique recommendations to each parent. Recommendations given based on feedback will be revised.
Study NCT04694872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation Based LSVT BIG Exercise Protocol
Description: Lee Silverman Voice Treatment-LOUD therapy is a protocol involving intensive speech therapy, which was initiated at the Lee Silverman Parkinson Center between 1987-1989 to heal hypophonia in individuals with PD. LSVT-BIG, on the other hand, is a protocol derived from LSVT-LOUD, used in neurorehabilitation, consisting of focused large-amplitude functional movements performed with great effort. Maximal Daily exercises consist of seven standard exercises. Functional component tasks, on the other hand, will be created for movements in which the patient has difficulty in daily life activities selected individually based on his complaints. In hierarchical tasks, daily life activities with difficulties will be studied with large amplitudes. Exercises will be applied simultaneously with the physiotherapist over the Zoom application, 4 days a week, 60 minutes a day, 4 weeks protocol respectively.
Study NCT04694872 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation Based Functional Balance and Mobility Exercise
Description: These exercises will be applied simultaneously with the physiotherapist over the Zoom application, 4 days a week and 60 minutes a day for 4 weeks.~Exercises will get harder with each passing week and its progression will be adjusted to the patient.
Study NCT05933161 — intervention group
Intervention type: DEVICE
Intervention: Freestyle Libre 3 Continuous Glucose Monitor (CGM)
Description: Subjects will be provided a Freestyle Libre 3 CGM for monitoring of blood glucose levels throughout participation in the study (approximately 3 months). CGM data will be uploaded to the LibreLink app on a weekly basis for review of glucose control and consultation with a diabetes-trained provider for any values outside of normal ranges. Adjustments to diet and medication therapy (antihyperglycemic therapy) will be made during consultations to improve episodes of hypoglycemia or severe hyperglycemia that were observed.
Study NCT05642052 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low carb diet
Description: low carb meals will be 50% less carbs than the regular meals
Study NCT05642052 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Regular diet
Description: Regular diet
Study NCT04441034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-convulsant medications
Description: Anti-convulsants are very commonly used to treat patients with chronic pain.
Study NCT04441034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-depressant medications
Description: Anti-depressants are very commonly used to treat patients with chronic pain.
Study NCT04784767 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)
Description: SpFN_1B-06-PL will be provided in a sterile, 2 mL single-use vial at 0.7 mL/vial, 90-110 ug/mL; ALFQ will be provided in a sterile 3 mL vial at 0.6 mL/vial
Study NCT04784767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride, USP, for injection (0.9% NaCl)
Description: Normal saline will be provided in a sterile, single-use 10 mL vial
Study NCT04784767 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)
Description: SpFN_1B-06-PL will be provided in a sterile, 2 mL single-use vial at 0.7 mL/vial, 90-110 ug/mL; ALFQ will be provided in a sterile 3 mL vial at 0.6 mL/vial
Study NCT06441890 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: 80mg/m2 IV D1, 8, 15
Study NCT06441890 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nab-paclitaxel
Description: 125mg/m2 IV D1, 8, 15
Study NCT06441890 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: 75mg/m2 IV D1
Study NCT06441890 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Trastuzumab
Description: 8mg/kg loading, then 6mg/kg IV/SQ D1
Study NCT06441890 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pertuzumab
Description: 840 mg loading, then 420mg IV/SQ D1
Study NCT05520541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Both groups will receive exercise-based training
Study NCT05520541 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Both groups will receive exercise-based training
Study NCT06331780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visual acuity
Description: VA will be measured with an Early Treatment Diabetic Retinopathy Study (ETDRS) chart
Study NCT06331780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Objective refraction
Description: Objective refraction will be measured using an auto-kerato-refractometer/aberrometer
Study NCT06331780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Objective monocular accommodation amplitude measurement
Description: Objective monocular accommodation amplitude measurements are obtained dynamically by measuring the subject's dioptric change while the participant focuses on a virtual object that moves from distance
Study NCT06331780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subjective monocular accommodation amplitude measurement with the Push-Up method
Description: The subjective monocular accommodation amplitude measurements are carried out by the push-up method and proceeds as follows:~* The ECP presents a near vision test card corresponding to a 0.8 (8/10) acuity line, or the smallest readable line if acuity is poor, or the smallest readable text.~* Instructions to the subject: Look at the smallest line of letters and try to see them clearly for as long as possible when I bring them closer; tell me when they start to blur and stay blurred.~* The ECP slowly brings the test card closer~* The ECP note the distance of the test card from the glasses as soon as the vision is blurred. Continue to move the test closer to check that vision remains blurred.~The amount of accommodation in this eye is equal to the proximity (= 1/distance) of the test when the blur is just perceived.
Study NCT06331780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subjective monocular accommodation facility measurement with the Rock method:
Description: The subjective monocular accommodation facility measurements are carried out by the Rock method and proceeds as follows:~* The ECP presents at 40cm a near vision test card corresponding to 80% of the VA.~* The ECP gives to the participant a flipper +/- 2 Dioptre~* Instructions to the subject: Look at the test and add the -2.00 D (Sphere) flipper, as soon as it's clear, return the flipper to present a +2.00 D (Sphere), as soon as it's clear, return the flipper etc... You have to do the maximum number of rotations in one minute.
Study NCT06331780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CISS Questionnaire
Description: This questionnaire relating to the use of the near vision will be submitted
Study NCT06331780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Difficulty assessment questionnaire
Description: After each near vision measurement, the participant should rate, on a Visual Analogic Score (0-10), the difficulty encountered, from 0: extremely easy to 10: extremely difficult. The participant may also specify the reasons for the difficulty(ies) encountered during the measurement.
Study NCT06331780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subjective evaluation questionnaire
Description: A subjective evaluation questionnaire will be submitted to the participants at the end of the visit.
Study NCT05817253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portrait
Description: In the context of audit and feedback interventions, Portrait is document produced by the physician organization 'Therapeutics Initiative' that provides personalized prescribing feedback for BC family physicians (FPs). Portraits are used as a practice resource tool for reflection on prescribing patterns. Each Portrait topic provides data of individual physician's prescribing practice, alongside the mean and median levels of their peers (other BC physicians), a succinct review of the best-available evidence on the topic, and recommendations for future action.
Study NCT05817253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutics Letter
Description: The Therapeutics Letter is a standalone publication that details identified problematic therapeutic issues in a brief, simple and practical manner. Therapeutics letters include a systematic literature review on a clinical topic, and help provide reference for the data presented in the Portraits.
Study NCT05191069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moringa Oleifera Mouthwash
Description: 15ml of the mouthwash to be used twice daily for 6 months
Study NCT05191069 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Mouthwash
Description: 15ml of the mouthwash to be used twice daily for 6 months
Study NCT04978311 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror therapy (MT) priming with task-specific training
Description: In the regimen, participants will perform MT first followed by task-specific training. After completion of MT, participants will practice task-specific training that emphasizes on restoration of essential skills for daily activities. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
Study NCT04978311 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mirror therapy priming with impairment-oriented training
Description: In the regimen, participants will perform MT first followed by impairment-oriented training. After completion of MT, participants will practice impairment-oriented training that emphasizes on restoration of movement. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
Study NCT04978311 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control therapy
Description: The control group will receive therapeutic training equivalent in duration to the two experimental groups. The control intervention will include practice of gross/fine motor activities, training of activities of daily living, practice to increase range of motions, muscle strengthening, as well as use of adaptive or compensatory technique to alleviate functional deficits. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
Study NCT04771585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Mask
Description: Fabric mask, no medical device
Study NCT04771585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgical Mask
Description: Medical face mask (personal protective equipment), CE-certified
Study NCT04771585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FFP2 respirator
Description: Filtering Face Piece with no less than 94% filtering capacity, CE-certified
Study NCT04771585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FFP3 respirator
Description: Filtering Face Piece with no less than 99% filtering capacity, CE-certified
Study NCT04836663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3525 tablet
Description: TQ-B3525 tablet administered orally once a day. Each cycle is 28 days.
Study NCT06323122 — intervention group
Intervention type: DEVICE
Intervention: 2.0 miniplates
Description: 2.0 miniplates
Study NCT06323122 — intervention group
Intervention type: DEVICE
Intervention: 2.3 high profile miniplates
Description: 2.3 high profile miniplates
Study NCT06323122 — intervention group
Intervention type: DEVICE
Intervention: 3D miniplates
Description: 3D miniplates
Study NCT04728126 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: The questionnaire will include socio-demographic information (i.e., gender, age, job seniority) and sub-scales for measuring study variables (i.e., menopausal symptoms, social and personal resources, burnout, and work ability).~Menopausal symptoms will be assessed using the Menopause-Specific Quality of Life questionnaire.~Job burnout will be measured through OBI inventory, which consists of 16 items describing the states of emotional exhaustion and detachment - two core dimension of burnout, and were developed to meet different occupational groups.~The menopause and the quality of working environment will be assessed using the Questionnaire developed by National Health Service in England and Wales.
Study NCT05079412 — intervention group
Intervention type: OTHER
Intervention: Chest ultrasound
Description: Chest ultrasound will be performed to eligiable (consented) patient after being on the respiratory support (NIV-NAVA vs NIPPV) for at least 24 hours. Both diaphragmatic function and lung ultrasound score will performed. Investigator interpreting the scans will be blind to patients type of respiratory support or clinical status.
Study NCT05315453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Rehabilitation
Description: 5-session Cognitive Rehabilitation intervention that can be administered over telehealth.
Study NCT05622812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Lyft Lidocaine
Description: Treatment for Jawline definition
Study NCT04257565 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wheeled Knee Walker
Description: The Wheeled Knee Walker allows total offloading of a healing limb and may diminish excessive force on the contralateral limb.
Study NCT04257565 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual and Customary Care
Description: This group will receive usual and customary care for treatment of their diabetic foot ulcer
Study NCT05484050 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Immunohistochemistry analysis
Description: Estimation of VEGF through Immunohistochemistry
Study NCT06178237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Purabond
Description: Application of Purabond to surgical field
Study NCT05697731 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vidiac Score
Description: Vidiac score is a scoring system created according to the visibility of laryngeal structures under videolarnyngoscopy in patients with expected difficult intubation.
Study NCT04692038 — intervention group
Intervention type: DEVICE
Intervention: Forceps biopsy combined with puncture biopsy under the guidance of Augmented Reality Navigation and Radial EBUS
Description: During the operation, under the guidance of Augmented Reality Navigation, the bronchoscope will reach the location of the target pulmonary nodules, and the EBUS probe will be inserted through the bronchoscope working channel, and gradually approach the target nodules to obtain EBUS images. After typical EBUS images are observed and the location is confirmed, the EBUS probe will be withdrawn and biopsy forceps and puncture biopsy needle will be used to obtain samples at the target locations respectively.
Study NCT05619978 — intervention group
Intervention type: OTHER
Intervention: 3L Therapy
Description: Treatments received in 3L were dasatinib, nilotinib, imatinib, ponatinib, bosutinib, and allo-SCT
Study NCT05619978 — intervention group
Intervention type: OTHER
Intervention: T315I
Description: Patients with chronic myeloid leukemia with T315I mutation
Study NCT05599789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab in Combination with Plinabulin and Docetaxel
Description: Pembrolizumab 200 mg Q3W IV infusion Day 1 of each 3-week cycle; Plinabulin 30 mg/m2 Q3W IV infusion Days 1 of each 3-week cycle; Docetaxel 75 mg/m² Q3W IV infusion Day 1 of each 3-week cycle.
Study NCT04663750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy
Description: Pars plana vitrectomy
Study NCT04663750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal 2 mg aflibercept (Eylea, Bayer) will be injected at baseline then monthly for two further doses, then 2-monthly until month 12
Description: Intravitreal 2 mg aflibercept (Eylea, Bayer) will be injected at baseline then monthly for two further doses, then 2-monthly until month 12.
Study NCT04663750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal 2 mg aflibercept (Eylea, Bayer) will be injected at baseline then monthly for two further doses, then 2-monthly until month 12
Description: Intravitreal 2 mg aflibercept (Eylea, Bayer) will be injected at baseline then monthly for two further doses, then 2-monthly until month 12.
Study NCT04663750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subretinal injection of recombinant TPA (Alteplase) up to a maximum of 25 micrograms in 0.2 mls
Description: Subretinal injection of recombinant TPA (Alteplase, Actilyse, Boehringer Ingelheim) up to a maximum of 25 micrograms in 0.2 mls.